Infrared Photobiomodulation for Epilepsy

This trial explores a new treatment using infrared light for individuals with drug-resistant epilepsy, a condition where seizures resist control by standard medications. Researchers aim to assess whether this light therapy, known as infrared photobiomodulation, can reduce seizures and evaluate its comfort for patients. It targets those with drug-resistant epilepsy who experience at least two seizures a month and maintain a detailed seizure diary. Participants will use this light treatment daily for six months. As an unphased trial, this study provides a unique opportunity for patients to explore innovative treatment options that might enhance their quality of life.

The trial does not specify if you need to stop your current medications, but you cannot participate if you are taking any medication that causes photosensitivity (makes your skin sensitive to light).

Research has shown that infrared light therapy is generally safe and well-tolerated. Studies indicate that this treatment does not cause significant side effects or harm to the brain. It is non-invasive, requiring no surgery or entry into the body. The devices used are easy to handle and have a strong safety record. Little to no evidence suggests harm or damage to body cells. This makes it a promising option for those seeking new treatments for epilepsy.¹²³⁴⁵

Unlike traditional epilepsy treatments that often rely on medications like antiepileptic drugs to control seizures, infrared photobiomodulation offers a novel approach by using light therapy. This method works by delivering infrared light to the brain, potentially reducing seizure frequency through cellular-level changes without the side effects commonly associated with medications. Researchers are excited because this non-invasive treatment might provide a safer, alternative option for those who do not respond well to conventional drugs.

Research has shown that infrared light therapy, administered as photobiomodulation in this trial, might help reduce seizures in people with epilepsy, particularly for those whose seizures resist medication. Animal studies have demonstrated that this treatment can decrease seizure activity by improving the function of mitochondria, the cell's power sources. This is significant because certain types of epilepsy are associated with mitochondrial dysfunction. Although more research is needed in humans, early findings suggest it could be a safe, non-drug option for managing epilepsy.¹⁶⁷⁸⁹